📊 CLRB Key Takeaways
Is Cellectar Biosciences, Inc. (CLRB) a Good Investment?
Cellectar Biosciences is a pre-revenue biotech company burning $4.8M annually with no commercialized products, representing high fundamental risk despite improving losses and adequate cash runway of ~1.7 years. While losses narrowed 51% YoY and the company maintains a strong cash position with minimal debt, the absence of revenue and negative operating cash flow underscore typical development-stage biotech financial distress. Success depends entirely on unproven clinical outcomes and pipeline advancement, not demonstrated business fundamentals.
Cellectar Biosciences shows the classic profile of a pre-revenue biotech with no operating income base, deeply negative cash flow, and very weak returns on capital. While the latest period shows a narrower net loss and a relatively clean balance sheet, the cash burn is far too high versus cash on hand, implying substantial financing dependence unless fundamentals improve quickly.
Cellectar Biosciences, Inc. Key Strengths (CLRB)
- Cash runway of approximately 1.7-2 years at current burn rate with $8.3M cash on hand
- Improving losses: net loss narrowed 51% YoY and EPS improved 80% YoY
- Minimal debt burden ($330.2K long-term debt) with favorable 0.10x debt-to-equity ratio
- Balance sheet leverage is low, with debt/equity of just 0.04x and minimal long-term debt
- Liquidity ratios are still acceptable at 2.96x, indicating near-term obligations are currently covered
- Net loss improved year over year, suggesting some expense control or non-operating improvement versus the prior period
CLRB Stock Risks: Cellectar Biosciences, Inc. Investment Risks
- Zero revenue generation with no clear commercialization timeline visible in financial statements
- Annual operating cash burn of $4.8M against minimal equity base of $3.3M creates dependency on successful capital raises
- Heavily negative returns (ROE -169.5%, ROA -50.8%) with no path to profitability evident from current fundamentals
- High cash burn relative to total assets (43% annual burn rate) and equity (145% annual burn rate)
- No revenue base is reported, making growth quality and business model validation highly uncertain
- Operating cash flow of -$23.12M against only $13.20M in cash implies a short cash runway and likely future capital raising
- Profitability remains deeply negative, with ROE of -255.2% and ROA of -145.5%, indicating poor capital efficiency
Key Metrics to Watch
- Cash runway depletion rate and timing of next funding requirement
- Operating cash flow trend and path toward positive cash generation
- Revenue milestones from clinical trial progression and commercialization events
- Quarterly loss trajectory to validate continued improvement toward breakeven
- Quarterly operating cash burn relative to cash balance
- Any emergence of recurring revenue or major reduction in operating losses
Cellectar Biosciences, Inc. (CLRB) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Cellectar Biosciences, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CLRB Profit Margin, ROE & Profitability Analysis
CLRB vs Healthcare Sector: How Cellectar Biosciences, Inc. Compares
How Cellectar Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cellectar Biosciences, Inc. Stock Overvalued? CLRB Valuation Analysis 2026
Based on fundamental analysis, Cellectar Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cellectar Biosciences, Inc. Balance Sheet: CLRB Debt, Cash & Liquidity
CLRB Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cellectar Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-41.89 indicates the company is currently unprofitable.
CLRB Revenue Growth, EPS Growth & YoY Performance
Cellectar Biosciences, Inc. Dividends, Buybacks & Capital Allocation
CLRB SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cellectar Biosciences, Inc. (CIK: 0001279704)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLRB
What is the AI rating for CLRB?
Cellectar Biosciences, Inc. (CLRB) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLRB's key strengths?
Claude: Cash runway of approximately 1.7-2 years at current burn rate with $8.3M cash on hand. Improving losses: net loss narrowed 51% YoY and EPS improved 80% YoY. ChatGPT: Balance sheet leverage is low, with debt/equity of just 0.04x and minimal long-term debt. Liquidity ratios are still acceptable at 2.96x, indicating near-term obligations are currently covered.
What are the risks of investing in CLRB?
Claude: Zero revenue generation with no clear commercialization timeline visible in financial statements. Annual operating cash burn of $4.8M against minimal equity base of $3.3M creates dependency on successful capital raises. ChatGPT: No revenue base is reported, making growth quality and business model validation highly uncertain. Operating cash flow of -$23.12M against only $13.20M in cash implies a short cash runway and likely future capital raising.
What is CLRB's revenue and growth?
Cellectar Biosciences, Inc. reported revenue of N/A.
Does CLRB pay dividends?
Cellectar Biosciences, Inc. does not currently pay dividends.
Where can I find CLRB SEC filings?
Official SEC filings for Cellectar Biosciences, Inc. (CIK: 0001279704) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLRB's EPS?
Cellectar Biosciences, Inc. has a diluted EPS of $-1.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CLRB's fundamental grade?
Based on our AI fundamental analysis in June 2026, Cellectar Biosciences, Inc. has a C grade with 79% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CLRB stock overvalued or undervalued?
Valuation metrics for CLRB: ROE of -169.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CLRB's AI grade for 2026?
Our dual AI analysis gives Cellectar Biosciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLRB's free cash flow?
Cellectar Biosciences, Inc.'s operating cash flow is $-4.8M, with capital expenditures of $3.4K.
How does CLRB compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -169.5% (avg: 15%), current ratio 1.90 (avg: 2).